Final results from a phase II study of infigratinib (BGJ398), an FGFR ...
2021年1月22日 · Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma …
Infigratinib (BGJ398) in previously treated patients with …
2021年8月3日 · Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally …
FDA Acceptance of New Drug for Infigratinib | BridgeBio
2020年12月1日 · Its lead investigational candidate is infigratinib (BGJ398), an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity that it believes, based on …
Phase II Study of BGJ398 in Patients With FGFR-Altered ... - PubMed
2018年1月20日 · Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective …
Infigratinib (BGJ398) | 99.9%(HPLC) | In Stock | FGFR inhibitor
Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, …
- 评论数: 230
Infigratinib (BGJ398) in previously treated patients with advanced …
Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic …
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 …
2017年1月10日 · Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant …
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 …
2018年7月1日 · BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 …
Infigratinib (BGJ-398) | FGFR Inhibitor | MedChemExpress
2016年9月18日 · Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, …
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 …
2016年11月21日 · BGJ398, an orally bioavailable, selective FGFR1 to 3 inhibitor (half maximal inhibitory concentration values range from 0.9 to 1.4 nM for FGFR1-3 to 60 nM for FGFR4), 19 …
- 某些结果已被删除